Ovarian function and fertility assessment
| Fertility assessment | Median age (years) | Sample | Cancer | Fertility assessment: AMH levels | Antral follicular count | |||||||||||||||||||||
| Article | Year | Study type | Patients included | BRCA mutated | BRCA 1 | BRCA 2 | BRCA WT | Other | BRCA mutated | BRCA 1 | BRCA 2 | BRCA WT | Other | Breast | Other | No cancer | BRCA mutated | BRCA 1 | BRCA 2 | BRCA WT | Other | BRCA mutated | BRCA 1 | BRCA 2 | BRCA WT | Other |
| Porcu et al17 | 2020 | Prospective | 227 | 32.2 | 31.5 | 33.2 | 32.5 | 32.4 | 22 | 11 | 11 | 24 | 181 | 46 | 0 | 181 controls | 2.8 | 1.2 | 4.4 | 4.5 | 3.8 | 11.65 | 11.8 | 11.5 | 14.2 | 12.48 |
| Ponce et al | 2020 | Case control | 135 | 32.35 | 32.6 | 32.1 | 32.7 | / | 69 | 32 | 37 | 66 | 0 | 0 | 0 | 0 | 2.77 | 3 | 2.54 | 2.27 | / | / | / | / | / | / |
| Oktay et al | 2020 | Longitudinal cohort | 108 | 33.7 | / | / | 36.1 | / | 14 | 0 | 0 | 59 | 35 not tested | 108 | 0 | 0 | 2.5 | 0 | 0 | 2.6 | 3.4 | / | / | / | / | / |
| Son et al | 2019 | Retrospective | 316 | 34 | / | / | 34 | / | 52 | 27 | 25 | 264 | 0 | 316 | 0 | 0 | 2.6 | 2.56 | 2.64 | 3.85 | / | / | / | / | / | / |
| Lambertini et al | 2019 | Prospective | 148 | 34 | / | / | 36 | / | 35 | 22 | 13 | 113 | 0 | 148 | 0 | 0 | 1.94 | 1.58 | 2.78 | 1.66 | / | / | / | / | / | / |
| Grynberg et al | 2019 | Retrospective | 329 | 31.7 | 31.8 | 31.9 | 32.3 | / | 52 | 36 | 16 | 277 | 0 | 329 | 0 | 0 | 3.6 | 3.7 | 3.2 | 4.1 | / | 20.5 | 21.3 | 18.4 | 21.7 | / |
| Lambertini et al | 2018 | Retrospective | 156 | 31 | / | / | 31 | / | 29 | 19 | 10 | 72 | 55 unknown | 156 | 0 | 0 | 1.8 | 1.8 | 1.5 | 2.6 | / | / | / | / | / | / |
| Gunnala et al | 2018 | Retrospective cohort study | 795 | 32.4 | / | / | 35.5 | / | 57 | 31 | 18 | 738 | 0 | 91 | 0 | 619 | 2.8 | 2.4 | 3.6 | 2.4 | / | 15.5 | 15.5 | 15.7 | 12.6 | / |
| Lin et al | 2017 | Comparative laboratory study | 30 | 36.5 | / | / | 33 | / | 18 | 13 | 5 | 12 | 0 | 0 | 0 | 0 | / | / | / | / | / | 11.2±6.7 primordial follicles/mm3 | 0 | 0 | 44.18±6.1 | No differences between BRCA1 and 2 |
| Johnson et al | 2017 | Prospective | 195 | 31.15 | 31.4 | 30.9 | 34.3 | 30.9 | 105 | 55 | 50 | 26 | 64 | 0 | 0 | 0 | 2.99 | 3.26 | 2.72 | 2.13 | 3.20 | / | / | / | / | / |
| Michaelson-Cohen et al | 2014 | Prospective | 365 | 33.2 | / | / | / | / | 41 | 26 | 12 | 324 | 0 | 0 | 0 | 0 | 2.71 | 2.48 | 1,71 | 2.02 | / | / | / | / | / | / |
AMH, anti-Müllerian hormone; WT, wild-type.